# A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

Source: https://onco.cc/trials/nct07196774/  
OnCo record `nct07196774` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab rezetecan, Docetaxel, Trastuzumab in her2-positive breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.

## Summary

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer is a phase 3 interventional study registered as NCT07196774 by Jiangsu HengRui Medicine Co., Ltd., with 740 participants enrolled, started 2025-10-23 and due to reach its primary completion in 2027-12. Interventions recorded: SHR-A1811 for Injection, Docetaxel injection, Trastuzumab Injection, Carboplatin for Injection, Pertuzumab Injection. Conditions listed: Early-stage or Locally Advanced HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07196774
- Phase: 3
- Setting: A Randomized, Open-label, Multicenter Phase III Study of SHR-A1811 Compared to Docetaxel+Carboplatin+Trastuzumab+Pertuzumab as a Neoadjuvant Therapy for the Initial Treatment of Early-stage or Locally Advanced HER2-positive Breast Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 740

## Sources

- ClinicalTrials.gov NCT07196774: https://clinicaltrials.gov/study/NCT07196774

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07196774.json